This biotechnology is about ex vivo transfection of messenger RNA to stem cells.
A solution of messenger RNA is mixed to a solution of our peptide, pepMB1, to form peptiplexes. These latter have been shown to deliver a large amount of mRNA to stem cells.
Peptides are biodegradables. Therefore, peptide, mRNA and mRNA-coded protein will all be broken down to aminoacids and nucleotides by intracellular proteases and RNases. Moreover, our second-generation mRNA (Aegis™) and pepMB1 do not possess any chemical modification that might be toxic to stem cells.
Asclepios gives rise to a very high level of mRNA-coded protein expression (luciferase activity over 109 RLU / mg of proteins, 16h post-transfection). Furthermore, in vitro transfected stem cells transiently express any protein of interest for several weeks (over 105 RLU / mg of proteins for three weeks).
One may choose the level of protein expression, 24 hours post-transfection, and the duration of protein expression by selecting the right mRNA 5’UTR, mRNA amount, transfection duration and amount of peptide. Thus, a high mRNA-coded protein expression can be achieved for 3 days to 3 weeks.
Shortly after their ex vivo transfection, stem cells might be injected to a tissue or embedded in a medical device. The mRNA-coded protein(s) might improve stem cell survival, adhesion or differentiation, or trigger local angiogenesis.
Messenger Biopharma has demonstrated the potency of Asclepios biotechnology in human mesenchymal stem cells.